King Edward

Implantica publishes Interim Report Q1, January - March 2022

Retrieved on: 
Wednesday, May 11, 2022
Medical device regulation, Investment, MDR, King Edward, King Edward VII Hospital, Organization, FDA, Congress, Lists of people executed in the United States, VP, EHealth, Mobile phone, Pharmaceutical industry

STOCKHOLM, May 11, 2022 /PRNewswire/ -- 

Key Points: 
  • Implantica continued during this quarter to substantially strengthen its organisation on a broad front.
  • Our regulatory and clinical teams have been diligently preparing the extensive RefluxStop PMA application for FDA approval in US.
  • We also continued to expand our presence in our US subsidiary, Implantica Inc.
    Cash and short-term investments as at the end of the period amounted to MEUR 125.7.
  • Implantica will hold a telephone conference on May 11 at 15:00 CET.